People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

New schizophrenia drug ‘could change the lives of millions of people’ - The US Food and Drug Administration has approved ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.

(Reuters) -Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not achieve ...